ArticleThe Journal of biological chemistry2026
CircAMOTL1 promotes adipose lipolysis and browning in cancer cachexia through miR-211-5p-mediated TET2 activation.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer cachexia is characterized by profound adipose tissue loss and metabolic remodeling, yet the regulatory mechanisms driving adipocyte dysfunction remain incompletely understood. Through whole-transcriptome sequencing of human subcutaneous adipose tissue, we identified circAMOTL1 as one of the most significantly upregulated circRNAs in patients with cachexia. circAMOTL1 expression positively correlated with weightloss severity and demonstrated strong diagnostic performance for cachexia. Functional studies revealed that circAMOTL1 promotes lipolysis and white adipose browning in adipocytes as evidenced by increased expression of ATGL, HSL, UCP1, and PGC-1α, elevated free fatty acid release, and enhanced mitochondrial content. Silencing circAMOTL1 produced the opposite phenotype. Mechanistically, circAMOTL1 localized predominantly in the cytoplasm and acted as a molecular sponge for miR-211-5p, thereby relieving miR-211-5p-mediated repression of TET2. Luciferase reporter, RIP, and FISH assays confirmed the circAMOTL1/miR-211-5p/TET2 regulatory interaction. Gain- and loss-of-function experiments demonstrated that TET2 is essential for circAMOTL1-induced lipolysis and thermogenic remodeling. In vivo, adipose-targeted recombinant AAV overexpression of circAMOTL1 in a C26 tumor-bearing mouse model induced adipose wasting and upregulated lipolytic and browning markers, phenocopying cachexia-associated adipose remodeling. These findings identify circAMOTL1 as a critical regulator of adipocyte metabolism in cancer cachexia. By modulating the circAMOTL1/miR-211-5p/TET2 axis, it drives lipolysis and thermogenic reprogramming of white adipose tissue. circAMOTL1 therefore represents a promising biomarker and a potential therapeutic target for preventing or attenuating cachexia-associated adipose tissue loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.